Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectorite BiomedicalROCO:4170 +3.57%69 Days Inventory is 145.24 as of Dec. 2025, which is 66% above its 10-year median of 87.55. GuruFocus rates ROCO:4170 with a GF Score™ of 69/100 and a GF Value™ of NT$17.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Vectorite Biomedical ranks better than 59.56% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Vectorite Biomedical's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vectorite Biomedical's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.58.
Vectorite Biomedical (ROCO:4170) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Vectorite Biomedical's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vectorite Biomedical's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Vectorite Biomedical Days Inventory Related Terms
Vectorite Biomedical Days Inventory Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Vectorite Biomedical's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Days Inventory distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical (ROCO:4170) has a Days Inventory of 145.24 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Vectorite Biomedical and its competitors. This is 66% above median its historical median of 87.55. Over the past decade, Vectorite Biomedical's Days Inventory has ranged from 34.69 to 143.80. According to the industry distribution chart, Vectorite Biomedical ranks #258 out of 638 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Vectorite Biomedical's Days Inventory too high?
Vectorite Biomedical's current Days Inventory of 145.24 is 66% above median its 10-year median of 87.55. Over the past 10 years, this metric has ranged from a low of 34.69 to a high of 143.80. The Biotechnology industry median Days Inventory is 183.20. Vectorite Biomedical's value of 145.24 is 20.7% below this industry median. Based on the distribution chart, Vectorite Biomedical ranks #258 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vectorite Biomedical has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #258 out of 638 companies for Days Inventory. This puts Vectorite Biomedical in the upper half of its industry. The industry median Days Inventory is 183.20. Vectorite Biomedical's value of 145.24 is 20.7% below this benchmark. Historically, Vectorite Biomedical's own Days Inventory has ranged from 34.69 to 143.80 over the past decade. While the company's 10-year median is 87.55 vs. the industry median of 183.20, Vectorite Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current Days Inventory of 145.24 is 20.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Vectorite Biomedical and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current Days Inventory is 145.24, which is 66% above median its own 10-year median of 87.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.58, compared to a current price of NT$13.05 — trading 25.8% below its estimated fair value. The current Days Inventory is 145.24, which is 66% above median its 10-year median of 87.55 and 20.7% below the Biotechnology industry median of 183.20. Vectorite Biomedical's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Days Inventory is 145.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$13.05 is trading 25.8% below its estimated GF Value™ of NT$17.58.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
Days Inventory: 145.24 (66% above median its 10-year median of 87.55)
GF Value™: NT$17.58 vs. price of NT$13.05 (25.8% below fair value)
Industry Position: 20.7% below the Biotechnology median (#258 of 638)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
69GF Score
Get the complete analysis for ROCO:4170
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
